Back to Trades
Grant4
AbbVie Inc.
ABBV
Total Value
$5.0M
Company Information
- Company Name
- AbbVie Inc.
- Ticker Symbol
- ABBV
- CIK
- 0001551152
Insider Information
- Name
- Thakkar Roopal
- Role
- Insider
- Location
- NORTH CHICAGO, IL
Filing Details
- Filing Date
- Feb 20, 2026
- Transaction Date
- Feb 18, 2026
- Accession Number
- 0002004979-26-000002
- Form Type
- 4
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Feb 18, 2026 | Common Stock, $0.01 par value | 6,015 | — | Grant/Award | — |
| Feb 18, 2026 | Common Stock, $0.01 par value | 2,138 | — | Grant/Award | — |
| Feb 18, 2026 | Common Stock, $0.01 par value | 3,346 | — | Grant/Award | — |
| Feb 18, 2026 | Common Stock, $0.01 par value | 6,638 | — | Grant/Award | — |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Feb 18, 2026 | Derivative | 21,937 | $230.04 | Grant/Award | $5.0M |
Footnotes
- (F1)Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
- (F2)Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
- (F3)Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
- (F4)Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
- (F5)Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,313 on February 18, 2027, 7,312 on February 18, 2028, and 7,312 on February 18, 2029.